Literature DB >> 8693440

Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease.

R Leung1, P Hill, J Burdon.   

Abstract

BACKGROUND: Inhaled morphine has previously been shown to increase exercise endurance in patients with chronic lung disease. A similar study was performed to determine whether inhaled morphine reduces the sensation of breathlessness in this group of patients.
METHODS: A randomised double blind study on the effect of nebulised morphine on both exercise induced breathlessness and maximum achievable power output using isotonic saline as a control was performed in 10 patients with stable chronic lung disease. Each subject performed a progressive exercise test (Jones' stage I) on an electrically braked cycle ergometer. The work load was increased by 10 watts per minute and subjects exercised to exhaustion. At the end of each minute of exercise patients were asked to rate their degree of breathlessness according to a modified Borg scale. All subjects were randomised to receive either inhaled morphine sulphate 1 mg/ml (5 ml) or isotonic saline (5 ml) by wet nebulisation. The effect of morphine and saline on the achieved exercise capacity and the development of breathlessness during exercise was tested on separate days.
RESULTS: The mean dose of morphine inhaled was 1.24 mg. There was no difference in maximum power output achieved, minute ventilation at maximum power output, nor the degree of breathlessness at maximum power output between the groups treated with morphine and placebo. The degree of breathlessness was related to the power output achieved during exercise by a power function relationship (mean r: morphine = 0.86, saline = 0.87). However, there was a wide variation in the sensation for any given power output in both groups. There was no difference in the group mean slopes (morphine = 1.15, saline = 1.00) or intercepts (morphine = 0.07, saline = 0.15) in this relationship between the morphine and saline treatment groups.
CONCLUSIONS: In patients with severe chronic lung disease inhaled morphine in the doses used in this study does not relieve exercise induced breathlessness nor does it increase maximum power output achieved during progressive exercise.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8693440      PMCID: PMC1090489          DOI: 10.1136/thx.51.6.596

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  18 in total

Review 1.  Chronic lung diseases and the perception of breathlessness: a clinical perspective.

Authors:  J G Burdon; M C Pain; A R Rubinfeld; A Nana
Journal:  Eur Respir J       Date:  1994-07       Impact factor: 16.671

2.  Do prostaglandins have a role in breathlessness?

Authors:  P A O'Neill; R D Stark; P B Morton
Journal:  Am Rev Respir Dis       Date:  1985-07

3.  Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases.

Authors:  A A Woodcock; E R Gross; A Gellert; S Shah; M Johnson; D M Geddes
Journal:  N Engl J Med       Date:  1981-12-31       Impact factor: 91.245

4.  Methods to assess breathlessness in healthy subjects: a critical evaluation and application to analyse the acute effects of diazepam and promethazine on breathlessness induced by exercise or by exposure to raised levels of carbon dioxide.

Authors:  R D Stark; S A Gambles; J A Lewis
Journal:  Clin Sci (Lond)       Date:  1981-10       Impact factor: 6.124

5.  Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers.

Authors:  A A Woodcock; E R Gross; D M Geddes
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-01

6.  Endorphins and the control of breathing. Ability of naloxone to restore flow-resistive load compensation in chronic obstructive pulmonary disease.

Authors:  T V Santiago; C Remolina; V Scoles; N H Edelman
Journal:  N Engl J Med       Date:  1981-05-14       Impact factor: 91.245

7.  Dihydrocodeine for breathlessness in "pink puffers".

Authors:  M A Johnson; A A Woodcock; D M Geddes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-26

8.  Effects of codeine on the respiratory responses to exercise in healthy subjects.

Authors:  R D Stark; P B Morton; P Sharman; P G Percival; J A Lewis
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

9.  Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease.

Authors:  A R Masood; J W Reed; S H Thomas
Journal:  Thorax       Date:  1995-06       Impact factor: 9.139

10.  Diazepam in the treatment of dyspnoea in the 'Pink Puffer' syndrome.

Authors:  P Mitchell-Heggs; K Murphy; K Minty; A Guz; S C Patterson; P S Minty; R M Rosser
Journal:  Q J Med       Date:  1980
View more
  11 in total

Review 1.  The management of dyspnea in cancer patients: a systematic review.

Authors:  Raymond Viola; Cathy Kiteley; Nancy S Lloyd; Jean A Mackay; Julie Wilson; Rebecca K S Wong
Journal:  Support Care Cancer       Date:  2008-01-24       Impact factor: 3.603

2.  Does nebulized fentanyl relieve dyspnea during exercise in healthy man?

Authors:  Houssam G Kotrach; Jean Bourbeau; Dennis Jensen
Journal:  J Appl Physiol (1985)       Date:  2015-03-12

Review 3.  A systematic review of the use of opioids in the management of dyspnoea.

Authors:  A-L Jennings; A N Davies; J P T Higgins; J S R Gibbs; K E Broadley
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

4.  The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide.

Authors:  Richard T Penson; Simon P Joel; Michael Roberts; Anna Gloyne; Stephen Beckwith; Maurice L Slevin
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

Review 5.  Management of specific symptom complexes in patients receiving palliative care.

Authors:  E Bruera; C M Neumann
Journal:  CMAJ       Date:  1998-06-30       Impact factor: 8.262

6.  Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study.

Authors:  Majid Shohrati; Mostafa Ghanei; Asghar Amini Harandi; Soniya Foroghi; Ali Amini Harandi
Journal:  Pulm Med       Date:  2012-03-19

Review 7.  Opioids: an unexplored option for treatment of dyspnea in IPF.

Authors:  Charlotte Kohberg; Charlotte Uggerhøj Andersen; Elisabeth Bendstrup
Journal:  Eur Clin Respir J       Date:  2016-03-10

8.  Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease - a randomised placebo-controlled trial.

Authors:  Sissel Kronborg-White; Charlotte Uggerhøj Andersen; Charlotte Kohberg; Ole Hilberg; Elisabeth Bendstrup
Journal:  Respir Res       Date:  2020-07-23

Review 9.  Palliative management of refractory dyspnea in COPD.

Authors:  Hope E Uronis; David C Currow; Amy P Abernethy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

10.  Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Linda Nici; Manoj J Mammen; Edward Charbek; Paul E Alexander; David H Au; Cynthia M Boyd; Gerard J Criner; Gavin C Donaldson; Michael Dreher; Vincent S Fan; Andrea S Gershon; MeiLan K Han; Jerry A Krishnan; Fernando J Martinez; Paula M Meek; Michael Morgan; Michael I Polkey; Milo A Puhan; Mohsen Sadatsafavi; Don D Sin; George R Washko; Jadwiga A Wedzicha; Shawn D Aaron
Journal:  Am J Respir Crit Care Med       Date:  2020-05-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.